SCORR Marketing and Applied Clinical Trials Release New Report
Kearney, NE. - SCORR Marketing, a global full-service marketing and communications firm, in partnership with Applied Clinical Trials, conducted a survey of clinical trial project managers to gain a better understanding of the level of company support they need and receive, the culture of their organizations and the biggest challenges they face in their jobs. “As the complexity of clinical trials increases, the demand for more proficient project managers increases as well,” said Cliff Echols, market intelligence director at SCORR. “The goal of this survey was to gain insight into the expectations and responsibilities of project managers that have been added as a result of the evolving nature of clinical trials.” The report details project managers’ current and desired levels of company support and training, and availability and importance of career development opportunities. It also reveals the most valuable skill sets for project managers to possess and their most challenging responsibilities. Survey respondents included program managers with varying levels of experience from international pharmaceutical companies, CROs, academic institutions, biotech companies and research sites. “Sponsors can use the results of this survey to make more insightful decisions and build stronger relationships with project management teams,” said Lisa Henderson, editor in chief at Applied Clinical Trials. About SCORR Marketing SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.
